These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 31064152)

  • 1. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
    Stella S; Zammit V; Vitale SR; Pennisi MS; Massimino M; Tirrò E; Forte S; Spitaleri A; Antolino A; Siracusa S; Accurso V; Mannina D; Impera S; Musolino C; Russo S; Malato A; Mineo G; Musso M; Porretto F; Martino B; Di Raimondo F; Manzella L; Vigneri P; Stagno F
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
    Rostami G; Hamid M; Jalaeikhoo H
    Gene; 2017 Sep; 627():202-206. PubMed ID: 28627443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
    Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
    Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance.
    Zhang J; Wang Y; Wang J; Hu J; Chen S; Jin J; Liu T; Zhou J; Hu Y; Ma D; Huang X; Ji C; Hou M
    Blood Cancer J; 2018 Jun; 8(7):61. PubMed ID: 29915172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
    Dulucq S; Etienne G; Morisset S; Klein E; Chollet C; Robbesyn F; Turcq B; Tigaud I; Hayette S; Nicolini FE; Mahon FX
    Ann Hematol; 2019 May; 98(5):1159-1168. PubMed ID: 30798348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors.
    Song HY; Noh H; Choi SY; Lee SE; Kim SH; Kee KM; Yoo HL; Lee MY; Kang KH; Suh JH; Yang SY; Jang EJ; Lee JI; Kim DW
    Cancer Med; 2018 Oct; 7(10):5107-5117. PubMed ID: 30171671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.
    El Missiry M; Hjorth-Hansen H; Richter J; Olson-Strömberg U; Stenke L; Porkka K; Kreutzman A; Mustjoki S
    PLoS One; 2017; 12(1):e0171041. PubMed ID: 28135325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia.
    Vasconcelos AP; Azevedo IF; Melo FCBC; Neves WB; Azevedo ACAC; Melo RAM
    Genet Mol Res; 2017 Apr; 16(2):. PubMed ID: 28437552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.
    Kim DD; Lee H; Kamel-Reid S; Lipton JH
    Br J Haematol; 2013 Mar; 160(5):630-9. PubMed ID: 23278256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.
    Eskazan AE; Sadri S; Keskin D; Ayer M; Kantarcioglu B; Demirel N; Aydin D; Aydinli F; Yokus O; Ozunal IE; Berk S; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):804-811. PubMed ID: 28847475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
    Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
    PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
    Lin HX; Sjaarda J; Dyck J; Stringer R; Hillis C; Harvey M; Carter R; Ainsworth P; Leber B; Pare G; Sadikovic B
    Eur J Haematol; 2016 Apr; 96(4):360-6. PubMed ID: 26059983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.
    Schäfer V; White HE; Gerrard G; Möbius S; Saussele S; Franke GN; Mahon FX; Talmaci R; Colomer D; Soverini S; Machova Polakova K; Cross NCP; Hochhaus A; Ernst T
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3081-3089. PubMed ID: 33677711
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Pagani IS; Dang P; Kommers IO; Goyne JM; Nicola M; Saunders VA; Braley J; White DL; Yeung DT; Branford S; Hughes TP; Ross DM
    Haematologica; 2018 Dec; 103(12):2026-2032. PubMed ID: 29976745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China.
    Shao H; Zeng Z; Cen J; Zhang J; Bai S; Wu C; Gong Y; Wang Y; Qiu H; Chen S; Pan J
    Leuk Lymphoma; 2018 Sep; 59(9):2152-2158. PubMed ID: 29334300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
    Vatanmakanian M; Tavallaie M; Ghadami S
    Cell Commun Signal; 2019 Apr; 17(1):38. PubMed ID: 31014357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
    Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
    Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.
    Branford S; Yeung DT; Ross DM; Prime JA; Field CR; Altamura HK; Yeoman AL; Georgievski J; Jamison BA; Phillis S; Sullivan B; Briggs NE; Hertzberg M; Seymour JF; Reynolds J; Hughes TP
    Blood; 2013 May; 121(19):3818-24. PubMed ID: 23515925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.